Lv31
266 积分 2025-04-30 加入
Predicting human subcutaneous bioavailability of monoclonal antibodies using an integrated in-vitro/in-silico approach
1小时前
待确认
Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies Using Human Intravenous Clearance or Antibody Isoelectric Point
3小时前
已完结
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers
1个月前
已完结
Strategies to reduce the use of non-human primates in the development of oncology therapeutics: CD3-bispecifics
1个月前
已完结
Hormone replacement therapy in children: The use of growth hormone and IGF-I
2个月前
已完结
Adherence and quality of life in children receiving rhGH treatment
2个月前
已完结
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB
2个月前
已完结
CHAPTER 8. ADME Properties of Peptide Therapeutics in Drug Discovery and Development
2个月前
已完结
Interrogating cyclic peptide natural products from an ADME perspective: Beyond cyclosporine A
2个月前
已完结
Cyclic Peptide Screening Methods for Preclinical Drug Discovery
2个月前
已完结
皖公网安备34019202002308
